The Effectiveness of Omalizumab Treatment in Real-Life is Lower in Patients with Chronic Urticaria Longer than 18 Months’ Evolution and Prior Immunosuppressive Treatment

[1]  A. Giménez-Arnau,et al.  Clinical Features of Chronic Spontaneous Urticaria that Predict Disease Prognosis and Refractoriness to Standard Treatment. , 2018, Acta dermato-venereologica.

[2]  L. Curto-Barredo,et al.  Omalizumab updosing allows disease activity control in patients with refractory chronic spontaneous urticaria , 2018, The British journal of dermatology.

[3]  Soichiro Matsushima,et al.  Efficacy and safety of omalizumab in Japanese and Korean patients with refractory chronic spontaneous urticaria. , 2017, Journal of dermatological science.

[4]  L. Billeci,et al.  Omalizumab for the Treatment of Chronic Idiopathic Urticaria: Systematic Review of the Literature , 2017, Pharmacotherapy.

[5]  Janko Brand,et al.  Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. , 2017, The Journal of allergy and clinical immunology.

[6]  P. Tuchinda,et al.  Omalizumab therapy for treatment of recalcitrant chronic spontaneous urticaria in an Asian population , 2017, The Journal of dermatological treatment.

[7]  I. Cherrez Ojeda,et al.  Omalizumab for chronic urticaria in Latin America , 2016, The World Allergy Organization journal.

[8]  M. Maurer,et al.  Effect of omalizumab on angioedema in H1‐antihistamine‐resistant chronic spontaneous urticaria patients: results from X‐ACT, a randomized controlled trial , 2016, Allergy.

[9]  S. Thomsen,et al.  Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients , 2016, The British journal of dermatology.

[10]  A. Giménez-Arnau,et al.  Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria , 2016, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  A. Secrest,et al.  The effect of omalizumab dosing and frequency in chronic idiopathic urticaria: Retrospective chart review. , 2016, Journal of the American Academy of Dermatology.

[12]  D. Solé,et al.  Omalizumab in Chronic Spontaneous Urticaria: A Brazilian Real-Life Experience , 2016, International Archives of Allergy and Immunology.

[13]  Z. Fedorowicz,et al.  Omalizumab in patients with chronic spontaneous urticaria: a systematic review and GRADE assessment , 2015, The British journal of dermatology.

[14]  Michihiro Hide,et al.  The EAACI/GA 2 LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update , 2015 .

[15]  S. Spector,et al.  Efficacy and Safety of Omalizumab in Patients with Chronic Idiopathic/Spontaneous Urticaria Who Remain Symptomatic on H1 Antihistamines: A Randomized, Placebo-Controlled Study , 2014, The Journal of investigative dermatology.

[16]  P. L. McCormack.  Omalizumab: A Review of Its Use in Patients with Chronic Spontaneous Urticaria , 2014, Drugs.

[17]  N. Agmon-Levin,et al.  Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience. , 2014, The Israel Medical Association journal : IMAJ.

[18]  T. Zuberbier,et al.  The EAACI/GA(2) LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. , 2014, Allergy.

[19]  J. Hébert,et al.  Real-life experiences with omalizumab for the treatment of chronic urticaria. , 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[20]  M. Maurer,et al.  Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. , 2014, Journal of dermatological science.

[21]  J. Bartra,et al.  Efficacy of omalizumab in chronic spontaneous urticaria refractory to conventional therapy: analysis of 110 patients in real-life practice , 2013, Expert opinion on biological therapy.

[22]  P. Kuna,et al.  Omalizumab in patients with symptomatic chronic idiopathic/spontaneous urticaria despite standard combination therapy. , 2013, The Journal of allergy and clinical immunology.

[23]  B. Rodrigo-Nicolás,et al.  Omalizumab in chronic urticaria: a retrospective series of 15 cases , 2013, Dermatologic therapy.

[24]  T. Casale,et al.  Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria. , 2013, The New England journal of medicine.

[25]  E. Kocaturk,et al.  Omalizumab markedly improves urticaria activity scores and quality of life scores in chronic spontaneous urticaria patients: A real life survey , 2012, The Journal of dermatology.

[26]  S. Spector,et al.  A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. , 2011, The Journal of allergy and clinical immunology.

[27]  J. Bousquet,et al.  Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report 1 , 2011, Allergy.